AstraZeneca’s second quarter of 2023 has been successful, with eight different medicines generating over US$1 billion in sales. The company has also seen positive results in eight separate Phase III oncology trials, with more data expected later this year.
Imfinzi, part of AstraZeneca’s immuno-oncology franchise, has experienced strong sales growth during this period, thanks to newly-approved uses. However, the company’s shares have been impacted by the Phase III TROPION-Lung01 (TL01) trial, where the absence of “clinically meaningful” results unsettled investors.
Following discussions with the FDA, AstraZeneca has announced its intention to make regulatory submissions based on the available data, which should address some initial concerns.
Shore Capital, a brokerage firm, believes that AstraZeneca’s results support the idea that the company offers a premium growth story. They highlight AstraZeneca’s strong portfolio of blockbuster drugs and an industry-leading pipeline, positioning the company for sustained growth in the long term.
The distraction caused by the TL01 trial has created a buying opportunity, according to Shorecap, which has set a target price of 13,000p.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.